Our latest paper in collaboration with Pfizer on the role of OCT2/MATE in creatinine clearance is accepted in JPET.
Due to the high costs associated with drug discovery and the clinical demand for effective drugs, in vitro human cell-based kidney models using renal proximal tubule epithelia are becoming popular tools for early-stage testing.
It is increasingly more important that in vitro models of renal drug transport are physiologically representative in order to accurately model nephrotoxicity and drug‑to‑drug interactions and predict or avoid incidences of drug-induced kidney injury in the later stages of development. In this article, Dr Colin Brown, director of ADMET technology at Newcells Biotech, discusses this further and considers future modelling options to address these challenges.
16th April, 2021
Dr Colin Brown
European Pharmaceutical Review. December 2020
Share on social media:
Don't miss out on our latest innovations: follow us on Linkedin